Brief: Bone Therapeutics FY Operating Loss Lowers To EUR 11.5 Mln

Biosenic SA

01/03/2019 06:24

March 1 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * FY REVENUES AND OPERATING INCOME OF EUR 5.1 MILLION, UP 20.5% COMPARED TO
2017
    * FY OPERATING LOSS FOR PERIOD AMOUNTED TO EUR 11.5 MILLION, COMPARED TO EUR
12.3
MILLION FOR FULL YEAR 2017
    * YEAR-END CASH POSITION OF EUR 8.2 MILLION COMPARED TO EUR 8.4 MILLION
YEAR-END
2017
    * COMPANY EXPECTS TO REPORT TOP LINE DATA IN MID-2019 FROM PHASE IIA STUDY
WITH
ALLOB IN 32 PATIENTS UNDERGOING A LUMBAR SPINAL FUSION PROCEDURE
    * IN SECOND HALF OF 2019, COMPANY PLANS TO SUBMIT A CTA WITH REGULATORY
AUTHORITIES IN EUROPE AND UNITED STATES FOR PHASE III PROGRAMME WITH JTA-004
    * NET CASH BURN FOR FULL YEAR 2019 IS EXPECTED TO BE IN RANGE OF EUR 13-14
MILLION
    * ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT ITS BUSINESS OBJECTIVES
UNTIL
END OF 2019
    * FY REVENUES AND OPERATING INCOME OF EUR 5.1 MILLION, UP 20.5% COMPARED TO
2017
    * YEAR-END CASH POSITION OF EUR 8.2 MILLION COMPARED TO EUR 8.4 MILLION
YEAR-END
2017
    * LOWER THAN ANTICIPATED NET CASH BURN OF EUR 13.9 MILLION VERSUS EUR 15-16
MILLION PREVIOUSLY GUIDED

Source text for Eikon:  ID:nGNE2b3LYt 
Further company coverage:  BOTHE.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))